Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

en and its development partner, Bayer HealthCare, will enroll patients into five global clinical trials:

  • COMMANDER-HF will evaluate XARELTO® in patients with chronic heart failure and significant coronary artery disease who are receiving standard care. The study will include 5,000 patients in 12 countries.
  • COMPASS will evaluate XARELTO® in patients with coronary artery disease or peripheral artery disease. This study includes 20,000 patients across 25 countries and will be conducted in collaboration with the Population Health Research Institute (PHRI) at McMaster University in Hamilton, Canada.
  • PIONEER AF-PCI will evaluate XARELTO® in 2,100 patients who have non-valvular atrial fibrillation and are undergoing percutaneous coronary intervention (PCI) with stent placement. The trial will assess XARELTO® in combination with dual antiplatelet therapy and when aspirin is not used.
  • X-VeRT will evaluate patients with atrial fibrillation scheduled for cardioversion – a medical procedure to convert abnormally fast heart rate to a normal rhythm, using electricity or antiarrhythmic medications. The study includes 1,500 patients across 17 countries and will compare XARELTO® to dose-adjusted vitamin K antagonist.
  • VENTURE-AF will evaluate the use of XARELTO® in patients with non-valvular atrial fibrillation undergoing catheter ablation, a procedure that uses energy delivered through catheters to eliminate the abnormal tissue that is causing the arrhythmia. The study will include up to 250 patients in four countries.

In addition, as part of our ongoing commitment to expanding therapeutic choices for health care professionals, Janssen recently announced<
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Following ... of their transactions, Array BioPharma Inc. (NASDAQ:  ARRY) ... and encorafenib definitive agreements with Novartis.  Along with ... an upfront payment of $85 million from Novartis. ... noted, "With the close of the Novartis-GSK transaction, ...
(Date:3/2/2015)... 2, 2015  The International Myeloma Foundation (IMF), ... myeloma patients while working toward prevention and a ... March to be Myeloma Awareness Month (#MAM). ... Awareness Month in 2009. Throughout the month, the ... community events, social media campaigns, story sharing, and ...
(Date:3/2/2015)... -- Cardinal Health today announced plans to acquire Johnson ... cardiology and endovascular devices, for $1.944 billion in cash, ... of tax benefits. The acquisition is expected to be ... senior unsecured notes and the remainder with existing cash. ... the United States and key non-U.S. countries ...
Breaking Medicine Technology:Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 2Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 4Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 5Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 6Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 7
... Dec. 8, 2011  RainTree Oncology Services (RainTree Oncology), ... and management services, today announced it has signed ... the nation,s largest privately-owned specialty pharmacy providing medication ... the Company to provide community oncology practices with ...
... 2011   Leatt Corporation (OTC: LEAT.PK), a global ... brace system designed to help prevent potentially devastating injuries ... today that the 2011 Annual Meeting (Meeting) of its ... Thursday, December 22, 2011.  Stockholders of record as of ...
Cached Medicine Technology:RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 2RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 3Leatt Corporation Announces 2011 Annual Shareholders' Meeting 2
(Date:3/2/2015)... 2015 ZoomCare announced today the ... healthcare. Zoom will expand its Portland on-demand neighborhood ... advanced care studios delivering urgent care, primary care, ... care and outpatient surgery. With its new neighborhood ... all healthcare needs outside of hospitalization. , “2015 ...
(Date:3/2/2015)... York (PRWEB) March 02, 2015 ... at Recovery Unplugged™—will be delivering a plenary address ... Perspective on the Art of Healing and Recovery ... (NCAD) and Behavioral Healthcare Executive Summit (BHES).     , ... Mr. Supa’s songs have been recorded by some ...
(Date:3/2/2015)... March 02, 2015 This year, the National ... and will provide opportunities for people across the country to ... help people with MS live their best lives. MS Awareness ... to inspire others to join the Society’s vision of a ... unpredictable, often disabling disease of the central nervous system, interrupts ...
(Date:3/2/2015)... Regulatory Compliance Associates® Inc. (RCA), ... and technical consulting, announces Mr. Seyed Khorashahi has ... , Before joining RCA, Mr. Khorashahi had over ... all aspects of developing safety-critical medical devices. ... Regulatory Compliance Associates Inc., Baxter Healthcare, and Beckman ...
(Date:3/2/2015)... Many mainstream media outlets have run stories ... how much of that news reporting is true? Many ... measles, but whose youngsters later developed autism, will assemble ... comprised of professionals, clinicians, researchers, therapists, advocates, and others. ... questions about the body and childhood health will have ...
Breaking Medicine News(10 mins):Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Growing List of Professionals Gather for World’s Most Comprehensive Autism Conference in Chicago, May 2015 2
... 18, 2008 TAP Pharmaceutical Products Inc. today reported ... new drug TAK-390MR, the first proton pump inhibitor (PPI) ... patients with erosive esophagitis (EE) and in maintenance of ... Disease Week (DDW) annual meeting in San Diego. , ...
... the 2000 census, Americans office workers spend an average ... work stations. Many recent studies on job satisfaction have ... environments, often under artificial light in windowless offices, report ... can employers make office environments more conducive to productivity ...
... 19 Volcano Corporation,(Nasdaq: VOLC ), a ... Optical Coherence Tomography (OCT) products designed,to enhance the ... said today that it will be participating in ... May 20., The presentation by Scott Huennekens, ...
... and progression of prostate cancer have eluded scientists ... have identified a specific gene expression profile of ... future treatments. The findings, published in BioMed Centrals ... that are differentially expressed in certain prostate cancer ...
... CHICAGO, May 19 SmithAmundsen LLC is pleased,to announce ... Chicago office,has been elected partner, effective May 17, 2008., ... Health Care practice group,focusing her work on health care ... Health Care Agencies, involving,the defense of both nursing and ...
... 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... rejoined the company in a part-time position ... owned subsidiary of Alexza. Mr.,Williams will have ... Singapore and establishing potential joint ventures in,Singapore. ...
Cached Medicine News:Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Greener offices make happier employees 2Health News:Volcano Corporation Presentation at JMP Conference to be Webcast 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:SmithAmundsen Elects New Partner, Linda F. Newman 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3
Inquire...
... - Anatomically designed to enhance the chin contour, ... mandible with a high-profile central chin projection. ... entire mandible, this implant provides a high central ... arms. Cleft Chin Implants - Designed with ...
... IEC CL40 and FL40 Centrifuge Series ... and versatility to increase your productivity ... broad array of rotors and accessories ... microplate applications, the IEC CL40 and ...
... Series offers unsurpassed versatility and exceptional ... liter benchtop centrifuge. With its broad ... high-speed centrifugation capabilities, the IEC CL31 ... to meet a variety of sample ...
Medicine Products: